All NewsFDA BriefsOncology IconsSpecial ReportsVoices from the Field
Conference CoverageConference Listing
All VideosCase-Based Peer PerspectivesExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPivotal Practice Views with the Oncology BrothersPodcastsPrecision Medicine
All PublicationsEvolving ParadigmsRoundtable Meetings SpotlightTargeted Therapies in Oncology
CME/CE
Case-Based Roundtable SeriesClinical TrialsPartnersPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
eNewsletterPrint Subscription
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
Multiple Myeloma
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Biomarker-Driven Lung Cancer
  • GIST
  • HER2-Positive Breast Cancer
  • Chronic Lymphocytic Leukemia
  • Small Cell Lung Cancer
  • Renal Cell Carcinoma
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
Multiple Myeloma
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CME/CE
Advertisement

Treatment With PARP Inhibitors for Patients With Ovarian Cancer : Episode 4

Part 2: Using PARP Inhibitors Beyond Recommended Duration in Ovarian Cancer

Mar 16, 2022
Targeted Oncology Staff

During a live virtual event, Adam C. ElNaggar discussed with participants whether patients who respond to PARP inhibitors for advanced ovarian cancer should continue to receive them indefinitely.

Adam C. ElNaggar, MD (Moderator)

Gynecologic Oncologist

Oncology Medical Director

Natera

Memphis, TN

Adam C. ElNaggar, MD (Moderator)

Gynecologic Oncologist

Oncology Medical Director

Natera

Memphis, TN

DISCUSSION QUESTION:

  • Would you continue treating a patient who has received PARP inhibitors for the full duration of maintenance therapy?

MICHAEL HEMPHILL, MD: I haven’t gotten to the 2-year mark for olaparib [Lynparza] or the 3-year mark for niraparib [Zejula],1 but if I got to that, I’d be very hard-pressed to stop if they’re doing it well. I think I’d almost treat it like imatinib [Gleevac] in a gastrointestinal stromal tumor scenario.2,3

ADAM C. ELNAGGAR, MD: Just keep running it?

HEMPHILL: Yes, I think so.

ELNAGGAR: Yes. That’s tough, and that conversation can be tough, too, In the front line, sometimes patients are ready to come off of it, but in the recurrent setting where their cancer antigen 125 is normal; they don’t have any symptoms; their CT scan’s negative; it’s time to come off of it. And [they say], “Look, you told me recurrence is incurable, and here I am, I want to stay on it.” Has anybody else run into that dilemma as to whether to stop at 2 or 3 years?

HASSAN GHAZAL, MD: I agree with what’s been said. In the first-line setting, it’s easier to tell the patients because of the cumulative toxicity, and in the first line where you think the [Kaplan-Meier] curve is more flat after you stop the treatment, at least from what we saw in SOLO-1 [NCT01844986] and others.4-6 It’s certainly weighing emerging toxicity versus benefit. I would feel more comfortable stopping in the first line, but as you said, in the recurrent setting it’s a different discussion. But you always weigh positives and negatives.

ELNAGGAR: I’m assuming all of you have experience with PD-L1 inhibitors and [similar regimens]. Those always recommend stopping at 18 months. Is this a hard-and-fast rule for you on immunotherapies, or do you generally keep those going? I know at our center, [opinions] are split. Some physicians will just keep on going because they’ll say there’s no evidence to stop, but others hold to that rule.

ZUHAIR GHANEM, MD: I feel this should depend on the bulk of the disease, and the degree of the metastatic disease. If you have a patient with bulky disease and more extensive stage IV metastatic disease as compared with more limited stage III disease, both of them will need the maintenance therapy because both of them are treated with up-front chemotherapy, but I would be more hesitant to stop treatment for the more bulky disease or the more widely-spread metastatic disease, than the patient with more limited disease.

ELNAGGAR: You’re talking about a patient that still has measurable disease, right?

GHANEM: Not necessarily. Even if the patient has no measurable disease, and the first scan showed more extensive disease then limited intra-abdominal disease that was completely removed by surgery, I feel the bulk of the disease, the patient age, and the patient tolerance really dictate if the 2-year duration is where to stop. It’s the same with lung cancer, too. The 2 years with immunotherapy is where most of the oncologists will probably stop. But, if you have a patient with a more widely spread disease up-front, and they responded so well to immunotherapy, I am usually hesitant to stop the treatment because I know how bad the disease was to start with. And, if it comes back, it won’t be easy to put it back to rest. That’s just my feeling.

VENU MADHAV KONALA, MD: For most patients who had a complete response, I generally stop after 2 years, but if they have a partial response and if they have 1 or 2 lesions left, I generally biopsy those lesions to see if they have active disease. If they have active disease, we go for other options like stereotactic radiation to get them off treatment, because they have oligometastatic disease with only 2 sites of disease.

ELNAGGAR: Yes, so you go after an oligo-metastasis at that point in time.

KONALA: Yes, at that time, if it’s still persistent. Based on the patient, we do different things. But generally, most clinical trials they stop the immunotherapy at 2 years in metastatic disease.

But obviously, as Dr Ghanem mentioned, if it is a widespread metastatic disease, most of us are uncomfortable [stopping treatment]. I had a patient with melanoma who went on [immunotherapy] for 5 years, and he doesn’t want to stop it. He’s not free of disease. It’s a discussion between you and the patient.

If it comes back, we can restart it, but some patients are very uncomfortable stopping it at that point, because they are doing so well and they don’t have any adverse events. They’re just coming once every 6 weeks, since pembrolizumab [Keytruda] is approved for every 6 weeks now, so some of them are very reluctant to stop if they have stage IV disease.7

ELNAGGAR: Yes, their initial tumor burden definitely plays into that in terms of the gestalt of [factors for] whether to stop or not.

References:

1. NCCN. Clinical Practice Guidelines in Oncology. Ovarian cancer/fallopian tube cancer/primary peritoneal cancer, version 1.2022. Accessed February 24, 2022. https://bit.ly/3BN2gC6

2. Lopes LF, Bacchi CE. Imatinib treatment for gastrointestinal stromal tumour (GIST). J Cell Mol Med. 2010;14(1-2):42-50. doi:10.1111/j.1582-4934.2009.00983.x

3. Balachandran VP, DeMatteo RP. Gastrointestinal stromal tumors: who should get imatinib and for how long?. Adv Surg. 2014;48(1):165-183. doi:10.1016/j.yasu.2014.05.014

4. Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495-2505. doi:10.1056/NEJMoa1810858

5. González-Martín A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391-2402. doi:10.1056/NEJMoa1910962

6. Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381(25):2416-2428. doi:10.1056/NEJMoa1911361

7. Pembrolizumab (Keytruda). Prescribing information. Merck & Co., Inc.; 2021. Accessed February 24, 2022. https://bit.ly/3hevcJY

EP: 1.Part 1: PARP Inhibition Recommendations in Advanced Ovarian Cancer

EP: 2.Part 2: Anderson Reviews Niraparib’s Efficacy in High-Risk Ovarian Cancer

EP: 3.Part 1: Addressing Toxicities of PARP Inhibitors for Ovarian Cancer

Now Viewing

EP: 4.Part 2: Using PARP Inhibitors Beyond Recommended Duration in Ovarian Cancer

EP: 5.Long-Term Follow-Up Shows Olaparib’s Efficacy in Ovarian Cancer

EP: 6.Niraparib Maintenance Shows Continued PFS Improvement in Ovarian Cancer

EP: 7.PAOLA-1 Shows Benefit from Olaparib After Bevacizumab in Ovarian Cancer

EP: 8.Niraparib Results Encourage Somatic Tumor Profiling in Ovarian Cancer

EP: 9.Adapting to Second-Line Restrictions of Niraparib in Ovarian Cancer

Related Videos
Related Content

Mirvetuximab Soravtansine Results from MIRASOL Deemed Practice-Changing for Frα+ Platinum-Resistant Ovarian Cancer

June 4th 2023

Maintenance Bevacizumab Combo Extends PFS in Ovarian Cancer

June 3rd 2023

Managing Adverse Events With Selinexor in R/R Multiple Myeloma

June 1st 2023

Olaparib/Abiraterone Shows rPFS Benefit in mCRPC Regardless of HRR Status

May 31st 2023

Reflecting on Real-World Evidence for Durvalumab in Unresectable Stage III NSCLC

May 25th 2023

Tolerability With Brentuximab Vedotin Treatment in Hodgkin Lymphoma

May 24th 2023

Mirvetuximab Soravtansine Results from MIRASOL Deemed Practice-Changing for Frα+ Platinum-Resistant Ovarian Cancer

June 4th 2023

Maintenance Bevacizumab Combo Extends PFS in Ovarian Cancer

June 3rd 2023

Managing Adverse Events With Selinexor in R/R Multiple Myeloma

June 1st 2023

Olaparib/Abiraterone Shows rPFS Benefit in mCRPC Regardless of HRR Status

May 31st 2023

Reflecting on Real-World Evidence for Durvalumab in Unresectable Stage III NSCLC

May 25th 2023

Tolerability With Brentuximab Vedotin Treatment in Hodgkin Lymphoma

May 24th 2023

Mirvetuximab Soravtansine Results from MIRASOL Deemed Practice-Changing for Frα+ Platinum-Resistant Ovarian Cancer

June 4th 2023

Maintenance Bevacizumab Combo Extends PFS in Ovarian Cancer

June 3rd 2023

Managing Adverse Events With Selinexor in R/R Multiple Myeloma

June 1st 2023

Olaparib/Abiraterone Shows rPFS Benefit in mCRPC Regardless of HRR Status

May 31st 2023

Reflecting on Real-World Evidence for Durvalumab in Unresectable Stage III NSCLC

May 25th 2023

Tolerability With Brentuximab Vedotin Treatment in Hodgkin Lymphoma

May 24th 2023
Related Content

Mirvetuximab Soravtansine Results from MIRASOL Deemed Practice-Changing for Frα+ Platinum-Resistant Ovarian Cancer

Mirvetuximab Soravtansine Results from MIRASOL Deemed Practice-Changing for Frα+ Platinum-Resistant Ovarian Cancer

June 4th 2023
Article

Kathleen N. Moore, MD says the phase 3 MIRASOL results bring a new standard-of-care to the FRα-high, platinum-resistant ovarian cancer landscape.

Read More


Maintenance Bevacizumab Combo Extends PFS in Ovarian Cancer

Maintenance Bevacizumab Combo Extends PFS in Ovarian Cancer

June 3rd 2023
Article

Phase 3 DUO-O study results reveal a promising strategy for patients with HRD-negative advanced ovarian cancer.

Read More


Managing Adverse Events With Selinexor in R/R Multiple Myeloma

Managing Adverse Events With Selinexor in R/R Multiple Myeloma

June 1st 2023
Article

During a Targeted Oncology™ Case-Based Roundtable™ event, Sumit Madan, MD, discussed with participants what challenges they face using selinexor in patients with relapsed/refractory multiple myeloma. This is the second of 2 articles based on this event.

Read More


Olaparib/Abiraterone Shows rPFS Benefit in mCRPC Regardless of HRR Status

Olaparib/Abiraterone Shows rPFS Benefit in mCRPC Regardless of HRR Status

May 31st 2023
Article

During a Targeted Oncology™ Case-Based Roundtable™ event, Alicia K. Morgans, MD, MPH, discussed results of the phase 3 PROpel trial of patients with metastatic castration-resistant prostate cancer. This is the second of 2 articles based on this event.

Read More


Reflecting on Real-World Evidence for Durvalumab in Unresectable Stage III NSCLC

Reflecting on Real-World Evidence for Durvalumab in Unresectable Stage III NSCLC

May 25th 2023
Article

During a Targeted Oncology™ Case-Based Roundtable™ event, Edward S. Kim, MD, MBA, and participants discussed the PACIFIC and PACIFIC-R studies of durvalumab in patients with unresectable stage III non–small cell lung cancer.

Read More


Tolerability With Brentuximab Vedotin Treatment in Hodgkin Lymphoma

Tolerability With Brentuximab Vedotin Treatment in Hodgkin Lymphoma

May 24th 2023
Article

During a Targeted Oncology™ Case-Based Roundtable™ event, Craig Moskowitz, MD, discussed the use of brentuximab vedotin in patients with Hodgkin lymphoma. This is the second of 2 articles based on this event.

Read More

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.